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Disease-related malnutrition is highly prevalent among cancer patients, with 40–80%
suffering from it during the course of their disease. Malnutrition is associated with
numerous negative outcomes such as: longer hospital stays, increased morbidity and
mortality rates, delayed wound healing, as well as decreased muscle function, autonomy
and quality of life. In cancer patients, malnutrition negatively affects treatment tolerance
(including anti-cancer drugs, surgery, chemo- and radiotherapy), increases side effects,
causes adverse reactions, treatment interruptions, postoperative complications and
higher readmission rates. Conversely, anti-cancer treatments are also known to affect
body composition and impair nutritional status. Tailoring early nutritional therapy to
patients’ needs has been shown to prevent, treat and limit the negative consequences
of malnutrition and is likely to improve overall prognosis. As the optimisation of treatment
outcomes is top priority and evidence for nutritional therapy is growing, it is increasingly
recognized as a significant intervention and an autonomous component of multimodal
cancer care. The proactive implementation of nutritional screening and assessment is
essential for patients suffering from cancer - given the interaction of clinical, metabolic,
pharmacological factors with systemic inflammation; and suppressed appetite with
accelerated muscle protein catabolism. At the same time, a nutritional care plan must be
established, and adequate individualized nutritional intervention started rapidly. Screening
tools for nutritional risk should be validated, standardized, non-invasive, quick and
easy-to-use in daily clinical practice. Such tools must be able to identify patients who
are already malnourished, as well as those at risk for malnutrition, in order to prevent or
treat malnutrition and reduce negative outcomes. This review investigates the predictive
value of commonly used screening tools, as well as the sensitivity and specificity of
their individual components for improving clinical outcomes in oncologic populations.
Healthcare professionals’ awareness of malnutrition in cancer patients and the pertinence
of early nutritional screening must be raised in order to plan the best possible intervention
and follow-up during the patients’ ordeal with the disease.
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INTRODUCTION
Disease-related malnutrition (DRM) is highly prevalent among
cancer patients with 40–80% suffering from it during the course
of their disease. Factors influencing DRM include among others
the type of cancer, the stage, location and nature of treatment
(1–3). DRM is a subacute and chronic condition resulting
from a deficit in energy, protein, and micronutrient intake
resulting in changes in body composition and reduced body
function which in turn negatively impact clinical outcome (4).
The European Society for Clinical Nutrition and Metabolism
(ESPEN) defines a cancer patient as “a patient with a cancer
diagnosis who is either waiting for or on cancer-directed
treatment, on symptomatic treatment, and/or receiving palliative
care” (5). They are consequently in different conditions at
treatment start (e.g., normal weight, overweight or obese),
undergoing various oncological treatments and reacting to them
in a different manner. Many cancer patients experience decreased
physiological and biological function, malnutrition, weight
gain/loss, fatigue, and psychological distress. Furthermore, many
patients experience metabolic changes and a systemic cytokine-
related inflammatory process followed by insulin resistance.
This metabolic state is associated with reduced appetite
(anorexia), increased muscle protein catabolism, and impaired
body function. All these factors may further worsen DRM and
potentially result in a multifactor wasting syndrome defined
as cachexia. It is therefore essential, as part of an adequate
multifaceted management regime, to identify and treat patients
at nutritional risk in the early reversible cachectic phase before
refractory cachexia occurs (6).
Unintentional weight loss is a major problem that impairs
body function, survival outcomes and quality of life (6, 7).
Unintentional weight loss >5% is experienced in a large
proportion of patients with gastric cancer (67%), pancreatic
cancer (54%) and lung cancer (35%), thus being the cancer
types where malnutrition is very prevalent (1, 8–10). DRM is
a common issue in the inhospital setting (32–34%) and the
outpatient setting (39%) (1, 11, 12). Approximately 20% of cancer
patients die from the consequences of DRM, rather than from the
primary disease itself (13, 14). Usually, DRM cannot completely
be reversed with a conventional diet and requires artificial
nutritional therapy. In an advanced stage when refractory
cancer cachexia occurs, the risks and burden of such therapy
possibly outweigh the potential benefit (6). DRM has negative
effects on health as a whole and is associated with numerous
negative outcomes such as increased morbidity and mortality
rates, longer hospital stays, delayed wound healing, as well as
decreases in muscle function, autonomy and quality of life (15).
In this population, DRM negatively affects treatment tolerance
(including anti-cancer drugs, surgery, chemo- and radiotherapy),
increases side effects, and causes adverse reactions, treatment
interruptions and postoperative complications. In addition, anti-
cancer treatments are also known to affect body composition and
nutritional state. Early nutritional therapy tailored to patients’
needs has been shown to prevent, treat, and limit the negative
consequences of DRM and may improve prognosis (16). As
evidence for the effectiveness of nutritional intervention is
growing, it should progressively become a significant part of the
multimodal cancer care.
As a first step in the nutritional management of oncologic
patients, the ESPEN recommends using a validated screening
instrument to assess the nutritional risk for both in- and
outpatients (5, 17–19). Screening tools for nutritional risk should
be validated by randomized controlled trials, standardized,
quick, and easy to use in daily clinical work. As already
mentioned, such tools must also be able to identify malnourished
or at-risk patients early on in order to prevent and treat
malnutrition and reduce negative outcomes. Although many
validated screening tools are available and applicable for both
oncologic in- and outpatients, there is no current gold standard
to detect the risk of DRM. None of the tools performs well
enough to consistently establish patients’ nutritional status, and
no screening or assessment tool on its own is capable of adequate
nutrition screening as well as predicting poor nutrition related
outcome (20).
Although international nutrition societies agree on the
necessity of systematic nutritional screening, it is not an
integrated part of standard care in most institutions (17, 21–
23). Studies have shown that without such procedures, over
50% of malnourished patients are not identified as at nutritional
risk or malnourished and remain untreated (24–26). In one
French study, 55% of patients reported reduced food intake after
receiving a cancer diagnosis, independent of their nutritional risk
category. Nutrition counseling was provided to only 41.4% of
those patients (26). In another French study, only 35.8% received
nutrition counseling, provided by dietitians (56.3%), hospital
practitioners (31.9%), or general practitioners (12.9%) amongst
others (27).
There is urgent need to raise oncologists’ awareness of the
need for early nutritional screening in cancer patients and
the necessity for providing rapid, individualized nutritional
intervention to reduce risk and severity of malnutrition
which could be detrimental to other clinical outcomes such
as survival and quality of life (28). Timely screening and
prompt identification of nutritional risk facilitates referral to
a dietician for nutrition management and leads to improved
outcomes (29). An Italian study demonstrated that clinicians
can be trained effectively to perform assessments identifying
malnutrition and its risks (3). An integrated nutritional
screening would help identify nutritional risk which must
then be addressed using a multidisciplinary approach.
Clinical team members must be aware which care setting,
population, and age group a tool was developed for before
implementing any given specific nutritional screening in their
institution (29).
The aim of this review is to present an overview of validated
nutritional screening tools, which enable quick identification,
therapy, and better outcome in oncological patients. It was
therefore designed to investigate the predictive value of
commonly used screening tools, as well as and the sensitivity
and specificity of their individual components regarding the
improvement of clinical outcomes in cancer patients.
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REQUIREMENTS AND PURPOSE OF
NUTRITIONAL SCREENING
The ESPEN guideline for screening states that “the purpose
of nutritional screening is to predict the probability of a
better or worse outcome due to nutritional factors, and
whether nutritional treatment is likely to influence this” (17).
Outcomes may therefore be defined as (i) the maintenance
and/or improvement of mental and physical function, (ii) the
reduction of treatment- and disease-related complications and
their severity, (iii) enhanced recovery, (iv) lower consumption of
resources, e.g., length of hospitalization.
A nutritional screening tool must detect the risk of
malnutrition, and/or predict whether it is likely to develop or
worsen under the present (and future) condition of the patient.
It should identify at-risk patients who are likely to benefit from
a consecutive nutritional intervention (sensitivity, predictive
validity). It should therefore include all parameters relevant to
the problem (content validity) and show low interrater variability
(reliability). Nutritional screening must assess four principles: (i)
the current condition, (ii) its stability (recent involuntary weight
loss), (iii) potential for worsening (reduced food intake) and (iv)
the negative influence of the disease (stressmetabolism associated
with severe disease). Using the body mass index (BMI) to define
nutritional risk is not reliable - in particular in cancer patients -
as other overweight patients who lose weight during treatment
would not be considered as at-risk patients, and assessment
of sarcopenic patients may be biased (21, 30). Each of these
parameters must be scored, providing risk quantification and a
direct link to subsequent intervention. An ideal screening tool
must be easy to conduct, rapid, non-invasive, not necessitate any
calculations or laboratory data, easily interpretable, reproducible
and inexpensive (21, 31).
According to the systematic review of van Bockhorst-de
van der Schueren et al., thirty-two screening tools have been
developed to assess patient nutritional risk (20). Of those
tools, twenty-four aimed to assess patient nutritional status
(identification of patients likely to benefit from nutritional
support), four aimed to predict clinical outcome (complications,
morbidity, length of hospital stay and mortality) and four aimed
to do both. Other additional tools have been designed for
specific populations and care settings. There is currently no “gold
standard” among the screening tools for malnutrition. They have
mostly been developed using full expert nutritional assessments
as a reference. They have also been validated by comparing
varying combinations. This has, as a result, meant that different
tools are applied in different populations and different settings,
and are yielding confusing results.
ESPEN guidelines on nutrition in cancer patients underline
the utmost importance of early nutritional screening as the first
step of nutrition management - ideally as soon as the cancer
diagnosis is made (5, 19). A thorough nutritional assessment
and consecutive care plan should be implemented based on the
patient’s level of risk. The Oncology Evidence-Based Nutrition
Practice Guideline for Adults recommends that each patient
should be screened for nutritional risk at entry in the oncology
clinic. Screening should be routinely repreated throughout the
treatment (29). Lastly, screening should initiate a specific action
protocol. At-risk patients should ideally be referred to a trained
dietician (nutritional consultation), whose comprehensive in-
depth nutritional assessment would then be used to tailor an
individualized nutritional care plan.
RECOMMENDED TOOLS FOR
NUTRITIONAL SCREENING
Several screening tools are available; each with its own individual
characteristics. ESPEN guidelines for cancer patients recommend
the use of the following four in cancer patients: Nutritional
Risk Screening 2002 (NRS 2002), Malnutrition Universal
Screening Tool (MUST) Mini Nutrition Assessment (MNA) and
Malnutrition Screening Tool (MST) (5, 19). The Academy of
Nutrition and Diet recommends the use of MST andMUST (29).
All these tools will be briefly presented below, in addition
to the Subjective Global Assessment (SGA) and the Nutriscore.
Table 1 summarizes the criteria used in each screening tool.
Nutritional Risk Screening 2002 (NRS 2002)
An ESPEN working group led by Jens Kondrup developed the
NRS 2002 in 2003 (18). It is recommended for hospitalized
patients and currently used extensively worldwide. The NRS 2002
was developed based on 128 studies showing the effectiveness
of nutritional intervention (18). Its purpose is to identify
malnourished hospitalized patients who are likely to benefit from
nutritional support. The NRS 2002 has been validated in over
100 clinical trials and is practical and quickly performed (2,
3min) (21, 30). It starts with a pre-screening of four questions.
If one is answered with “yes,” a complete screening must be
performed. The NRS 2002 is based on impairment of nutritional
status (percentage of weight loss, general condition, BMI, and
recent food intake), disease severity (stress metabolism), and age.
Each category is rated from 0 (normal) to 3 (severe), and an age
≥70 years adds 1 point. Total scores range from 0 to 7 points.
Patients with a total score ≥3 classified as “at nutritional risk”
could benefit from nutritional support and improved clinical
outcome (18).
Malnutrition Universal Screening Tool
(MUST)
The Malnutrition Advisory Group of the British Association for
Parenteral and Enteral Nutrition developed MUST in 1992 to
identify patients at nutritional risk, and to predict their clinical
outcome (33, 34). It is recommended for outpatient screening by
the ESPEN Society and has been validated in various care settings
and populations (35). It is similar to the NRS 2002 and includes
the following criteria: unintentional weight loss, BMI, and food
intake (acute disease-related effect inducing a phase of >5 days
with no food intake). Each criterion is rated from 0 to 2. All points
are added up and patients with an overall score ≥2 are classified
as at nutritional risk.
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TABLE 1 | Criteria used for the nutritional screening in different tools, modified according to (2, 32).
Criteria Nutritional screening tools
NRS 2002 MNA MUST MST SGA PG-SGA Nutriscore
Unintentional weight loss x x x x x x x
BMI x x x
Appetite x x x
Food intake x x x x x x x
Muscle mass/function/mobility x x x
Disease state x x x
Age x
Neuropsychological aspects x
Mini Nutrition Assessment (MNA)
The MNA was developed to assess the nutritional status in
older people who may be frail, living in long-care facilities, or
hospitalized (36). It has been validated through independent
clinical record assessments by trained physicians, and
comprehensive surveys of food intake, biochemical parameters,
and anthropometric measurements (37). The MNA includes
eighteen items in four categories: anthropometric, general,
dietary, and subjective assessment (38). As administering the
MNA is time-consuming (15min), a shorter version with six
items has been developed. It retains the accuracy and validity
of the full MNA and only takes about 4min to complete. The
final tallied score ranges from 0 to 30 for the full version and
0 to 14 for the short form. Scores of 17–23.5 indicate risk for
malnutrition; with <17 indicating malnutrition in the full
version and ≤11 signaling a risk for malnutrition in the shorter
version (39).
Malnutrition Screening Tool (MST)
Ferguson et al. developed the MST in 1999. It is a quick screening
tool, easy to apply, and includes questions on appetite, food
intake, and recent weight loss (31). The sum of both categories
totals scores ranging from 1 to 5, whereby a ≥2 calls for action.
The MST has been well-validated in both in- and outpatient
populations (31).
Subjective Global Assessment (SGA)
The SGA was developed by Detsky et al. in 1987 (40). It identifies
patients at nutritional risk and predicts clinical outcomes, and is
rather an assessment than a screening tool as it combines medical
history with clinical findings. In addition to issues addressed in
other screening tools (weight loss, food intake) the SGA also
includes: symptoms possibly influencing food intake, functional
capacity, physical examination, and the opinion of the clinician
in charge. It is easy to learn, efficient, and used in various clinical
settings. It does however require training for the clinicians
which is quite time-consuming and often perceived as additional
workload (41, 42). The SGA targets chronic and advanced cases
of malnutrition (43, 44).
The patient-generated SGA (PG-SGA) is the result of items
added and changed over time to more specifically meet the
needs of cancer patients and involve them directly in the process









Kappa >0.6 Kappa 0.4–0.6 Kappa <0.4
(13, 45–47). The PG-SGA has been validated in cancer patients
and is the most accepted and widely-used screening tool for this
population (45, 47–51).
Nutriscore
The Nutriscore was recently developed for oncology outpatients
as an expert consensus from different dietetic and nutrition
units from the Catalan Institute of Oncology on the basis of
the MST (52). It includes questions to unintentional weight loss.
Additionnally, it includes specific oncologic parameters such
as tumor location and anti cancer treatment. The sum of all
categories ranges from 0 to 11 points, whereas total score ≥5
points calls for action, i.e., referral to a dietician.
VALIDATION OF SCREENING TOOLS IN
THE ONCOLOGY POPULATION
Validation of screening tools is important as it shows whether the
tool is able to detect what it is intended to or not. Table 2 shows
the rating for validation results used in this review. Assessing and
reporting the validity of a tool within a defined population and
care setting is paramount to ensuring its suitability (21). Despite
the relatively high number of nutritional screening tools, very
few have been validated in oncologic patients. Unfortunately,
study results also differ widely, not only for the various tools,
but also between studies using the same tools in differing care
settings. The true validity of many tools remains unclear due to
methodological concerns in the respective studies (53).
Moreover, it may be misleading to validate a screening
tool in the oncologic population as there are many different
types of cancer types, stages, sites, etc. The type of treatment
received as well as the care setting (in - vs. outpatients) may
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also influence results. Various screening tools include symptoms
that potentially affect nutritional status, e.g., fatigue, pain,
gastrointestinal symptoms. These symptoms have been shown to
be highly specific (91.1%) but rather poorly sensitive (43.3%),
leading to under recognition of at-risk patients (31). Ravasco
et al. have shown that, in some types of cancer, the impact of
nutritional status deterioration and the reduction of food intake
may be more relevant than the stage or site (54). Further, many
screening tools assess BMI possibly omitting an impaired body
composition, as in overweight/obese patients or in patients with
ascites and/or oedema in which there is no change in body
weight and the BMI is adequate, but there is an important
nutritional impairment.
VALIDITY AND PROGNOSTIC VALUE OF
VARIOUS SCREENING TOOLS
Table 3 shows the summary of evidence regarding the validation
of the presented nutritional screening tools in the oncologic
population.
SGA
The SGA is the oldest assessment tool and was in fact based
on clinical evaluations. It aims to analyse patient nutritional
risk and predict postoperative outcomes (61). SGA is most
frequently referenced as a predictor of clinical outcomes. Its fair-
to-good validity has been demonstrated by correlating objective
measurement of nutritional status with clinical classification
and with measurements of hospital morbidity (antibiotics use,
infections, length of stay) (61). The construct validity of the
SGA remains controversial (61). It has been validated in the
oncologic outpatient population, showing high sensitivity of 96%
and good specificity of 83%; indicating a high degree of interrater
agreement (20).
PG-SGA
The PG-SGA was derived from the SGA for the oncology
population and is considered the gold standard for oncology by
the Oncology Nutrition Dietetic Practice Group of the American
Dietetic Association (56, 62). PG-SGA has been validated in
ambulatory oncology settings. It is highly sensitive and specific
and is widely used in other care settings (45, 47, 55). It performs
well compared to other tools and is therefore used to validate
the other screening methods (57). The PG-SGA closely correlates
with patient weight loss in the previous 6 months, length of
hospital stay, and quality of life (45, 55). Its sensitivity regarding
nutritional risk, however, is poor (40, 63). It functions more for
assessment than screening and requires time and training.
MUST
The content validity of the MUST is also ensured as it was
developed by a multidisciplinary working group. It is rated as
highly reproducible, consistent, and reliable (κ = 0.88–1.00)
by health care professionals (34). Predictive validity in the
community setting was established based on studies investigating
the effect of (semi)starvation on mental and physical function
in healthy volunteers. This has also been extended to other care
settings, where it has shown fair-to-good validity. The MUST
has been specifically validated in cancer patients showing low
sensitivity and specificity (1, 4, 54, 59, 60). It demonstrates
good predictive validity for clinical outcome (length of hospital
stay and mortality), for rate of hospital admissions, and for the
number of visits to general practitioners (35).
Nutriscore
The Nutriscore is a recent score and proven to be rapid, simple
and effective in the outpatient setting. It does not perform better
than the MUST in the inpatient setting (47, 64).
MST
TheMST was developed based on the SGA for adult inpatients. It
shows fair-to-good validity in this setting (31), which has been
confirmed by various studies (31, 55, 60). The MST is a poor
predictor for clinical outcome. Compared to NRS 2002 and PG-
SGA, the MST performs well in cancer outpatients but poorly
in cancer inpatients (57). It is however not predictive for the
hospital length of stay in those populations (25).
The MST may also be completed by outpatients themselves
and results show high intra- (κ = 0.88) and interrater reliability
(κ = 0.92) when compared with dieticians (65). The patient-
led MST was tested against the SGA, also showing good validity
(sensitivity 94% and specificity 86%) (65).
NRS 2002
The NRS 2002 is known for its high content validity as it
was developed by an ESPEN working group and based on
the available literature. Its reliability has been validated by a
wide range of health care professionals (nurses, dieticians, and
physicians, κ = 0.67 and κ = 0.76 among physicians) (18).
The predictive validity of the NRS 2002 was demonstrated
by retrospectively analyzing 128 randomized controlled trials
on nutritional support, where patients at risk according to
the NRS 2002 showed a higher likelihood of positive clinical
outcome (41). Increasing number of prospective randomized
controlled trials investigating the effect of nutritional support
in mixed populations (including cancer patients) using the NRS
2002 show improved clinical outcome (reduced length of stay,
complications, and mortality) (64, 66). NRS 2002 demonstrates
a fair-to-good validity in mixed hospital populations (20,
66). Ravasco et al. found the NRS 2002 total score to be
satisfactory in cancer patients with regard to correlations of
recognized prognostic factors (such as tumor type, symptoms, or
performance status) (54).
MNA
The MNA was developed for the elderly population and was
originally validated by dietician assessment. Validity of the
specific contents has not been reported to date, but its reliability
was shown to be fair (κ = 0.51) (36). The short form is accepted
to be as valid as the full version. The MNA has been studied
in all care settings and has a good validity in the elderly in
the community, while its validity in hospital settings is poor-
to-fair (36–39, 59). There is currently no evidence for the
predictive validity of clinical outcome (length of hospital stay,
Frontiers in Nutrition | www.frontiersin.org 5 April 2021 | Volume 8 | Article 603936
Reber et al. Nutritional Risk Screening in Cancer
TABLE 3 | Evidence for nutritional screening in the oncologic population.












Bauer et al. (45) Cancer inpatients PG-SGA SGA 71 76 SGA 98 82 95 +
93–
Good
Isenring et al. (55) Cancer outpatients MST PG-SGA 50 34 MST
26 PG-SGA
100 92 Good
Ferguson et al. (31) Cancer outpatients
undergoing
radiotherapy
MST SGA 106 11 SGA
28 MST
100 81 40 +
100–
Good








Boléo-Tomé et al. (56) Cancer patients
referred for
radiotherapy
MUST PG-SGA 450 31 MUST
29 PG-SGA
80 89 87 +
100–
Good
Shaw et al. (57) Cancer inpatients MST PG-SGA 128 71 PG-SGA
52 MST





Cancer patients Nutriscore MUST 93 44 Nutriscore
70 MUST
59 89 93 +
48–
Fair
Read et al. (42) Cancer patients MNA PG-SGA 157 66 MNA
65 PG-SGA
97 54 59 + Fair









Bauer et al. (59) Cancer inpatients MUST SGA 65 59 75 Poor






Schwegler et al. (12) Cancer inpatients
undergoing colorectal
surgery
NRS 2002 – 186 39
Bozzetti et al. (1) Cancer outpatients NRS 2002 – 1000 34
Gupta et al. (48) Ovarian cancer
patients
SGA – 132 50
complications, and mortality) in the elderly population. The
MNA lacks specificity for cancer patients due to the inclusion
of some criteria, e.g., the use of three medications per day or
three full meals per day (42), and its usage in the oncologic
population is poorly evaluated (21, 42, 50). One study performed
in lung cancer patients demonstrated a better predictive and
prognostic value of MNA compared to weight loss alone in the
initial evaluation of the impaired nutritional state (67).
OUTLOOK
Future studies should focus on the validation of nutritional
screening tools specifically for oncologic patients - especially
as oncologic outpatient numbers are growing. There is a need
to further investigate the challenges and differences between
identifying risk in oncology outpatients (majority) vs. inpatients
(few). Bozzetti et al. reported that 32% of cancer outpatients at
nutritional risk in their study had not received treatment, even
though 14% had an NRS 2002 total score >3 (1).
One German survey of certified oncologic care centers showed
that only around 30% of patients received nutritional counseling
during their cancer ordeal (regardless of their nutritional status)
and in fact, one third of patients screened were actually
at nutritional risk. Furthermore, none of the centers had a
systematic screening procedure in place and only very few had
dieticians available (68). There is an urgent need for action to
fill these gaps. The nutritional care process must become an
integral part of oncologic outpatient treatment. Evenmore recent
- oncology tailored- plus other ongoing efforts still do not seem to
provide us with the solutions, so needed to tackle these prevalent
issues in this still under served critical population. There are
efforts to provide guidance/indicators which might attempt to
reflect/identify malnutrition, as for example the GLIM criteria –
a diagnostic and operational framework, and not a measurement
tool. One could argue that, ultimately, albeit considering risk
definition, it might be worth exploring, as it might well prove
suited to better reflect the stratified/personalized nature of
oncology, and just might offer an alternative to the traditional
approach of a “one size fits all” tool. Future efforts should
concentrate on the predictive and prognostic value of each
criteria of the screening tools, as it can be expected that all of them
will have different weights across such diverse presentations, as
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it is with oncology- i.e., disease biology, organ, stage, treatment
stage, etc. Establishing predictive and prognostic criteria is of the
utmost importance in a field like oncology.
CONCLUSION
Screening tools are the first step in the nutritional care process.
All screening tools presented in this review substantially or
moderately agree with each other. Some may help detect
nutritional risk, others may predict clinical outcome, others
do both in defined populations. There is currently no general
screening tool which can predict clinical outcome in every patient
group, in all care settings - especially not for the oncologic
population mainly due to the heterogeneity of the disease within
patient groups and treatment settings. Additionally, the cancer
care journey of each patient is unique – the disease itself is
very different within each individual patient. The quick and
easy screening tools mostly lack sensitivity. High sensitivity may
be preferred to higher specificity for screening tools. Patients
identified as being at high nutritional risk should undergo further
assessment by a dietician and receive an individualized care plan.
Health care professionals must be aware of these limitations
and implications while screening patients, and must carefully
select the appropriate nutritional screening tool depending on the
target population, care setting, etc. The validation of screening
tools in the oncologic population is inadequate, however,
screening is still the most important goal. Consistent integration
across the board of the oncology care pathways should be
achieved. As malnutrition remains a distressingly undertreated
issue, early screening and consecutive rapid initiation with
adequate nutritional support should be an integral part of the
multimodal oncologic regime – always with the intention of
maintaining and improving patients’ clinical outcome and quality
of life.
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